1. Home
  2. MTSR vs HASI Comparison

MTSR vs HASI Comparison

Compare MTSR & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTSR
  • HASI
  • Stock Information
  • Founded
  • MTSR 2022
  • HASI 1981
  • Country
  • MTSR United States
  • HASI United States
  • Employees
  • MTSR N/A
  • HASI N/A
  • Industry
  • MTSR
  • HASI Real Estate Investment Trusts
  • Sector
  • MTSR
  • HASI Real Estate
  • Exchange
  • MTSR NYSE
  • HASI Nasdaq
  • Market Cap
  • MTSR 3.0B
  • HASI 3.4B
  • IPO Year
  • MTSR 2025
  • HASI 2013
  • Fundamental
  • Price
  • MTSR $29.60
  • HASI $25.65
  • Analyst Decision
  • MTSR Strong Buy
  • HASI Strong Buy
  • Analyst Count
  • MTSR 6
  • HASI 9
  • Target Price
  • MTSR $55.25
  • HASI $38.33
  • AVG Volume (30 Days)
  • MTSR 1.0M
  • HASI 1.5M
  • Earning Date
  • MTSR 05-12-2025
  • HASI 07-31-2025
  • Dividend Yield
  • MTSR N/A
  • HASI 6.49%
  • EPS Growth
  • MTSR N/A
  • HASI N/A
  • EPS
  • MTSR N/A
  • HASI 1.08
  • Revenue
  • MTSR N/A
  • HASI $126,702,000.00
  • Revenue This Year
  • MTSR N/A
  • HASI $189.49
  • Revenue Next Year
  • MTSR N/A
  • HASI $14.03
  • P/E Ratio
  • MTSR N/A
  • HASI $23.96
  • Revenue Growth
  • MTSR N/A
  • HASI N/A
  • 52 Week Low
  • MTSR $12.30
  • HASI $21.98
  • 52 Week High
  • MTSR $37.99
  • HASI $36.56
  • Technical
  • Relative Strength Index (RSI)
  • MTSR N/A
  • HASI 46.13
  • Support Level
  • MTSR N/A
  • HASI $25.28
  • Resistance Level
  • MTSR N/A
  • HASI $27.88
  • Average True Range (ATR)
  • MTSR 0.00
  • HASI 0.73
  • MACD
  • MTSR 0.00
  • HASI 0.01
  • Stochastic Oscillator
  • MTSR 0.00
  • HASI 37.88

About MTSR METSERA INC

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: